Earkart LimitedQ3 FY25
Earkart Limited
Q3 FY25 Earnings Call Analysis
Management growth scorecard
Revenue
Category 2
Margin
Category 3
Fundraise
N/A
Order
Yes
Capex
Yes
2 of 4 growth signals are positive.
Full analysisRevenue guidance
Category 2- →Earkart aims to reach approximately ₹300 crore turnover in 5 years (by 2030).
- →Targeting 500 to 550 clinic installations by FY 2027, with installation cost per device around ₹2.7 lakh per clinic.
- →Expecting a compound annual growth rate (CAGR) of about 25% this year and aiming to sustain similar growth next year.
- →Private sector revenue share expected to grow to about 70% within 5 years, with government orders range-bound around 20-30%.
- →Revenue from clinics expected to rise significantly, e.g., from 110 clinics generating roughly ₹10-11 crore at full capacity.
- →Focus on expanding geographical presence across India, moving from North to West, South, and eventually East.
- →Anticipate operational cost enhancements with increased hiring and infrastructure to support expansion; margins expected between 20-30% EBITDA.
- →Private market margins up to 40-45% gross margin projected with increasing private sector focus.
Margin guidance
Category 3- →Earkart aims to become a ₹300 crore company within 5 years (by 2030).
- →Target to scale up to 500-550 clinics by FY27, with ~₹70,000 installation cost per clinic, funded by IPO proceeds.
- →EBITDA margins expected between 20-30%, aiming for 23% EBITDA margin this year as expansion costs stabilize.
- →Gross margins around 40-45% on private sales; government segment margins at 29-32%.
- →Private sector revenue share expected to increase to ~70% by 2028, with government orders range-bound at 20-30%.
- →Long-term growth driven by expansion beyond North India to West and South, then East regions.
- →Operating efficiency expected to rise to 70-80% in 12-19 months, improving margins further.
- →EPS growth implied via scaling revenue and maintaining healthy margins, with profitability improving as expansions mature.
Sign up free to read the full earnings analysis
Get access to all 5 sections — revenue, margin, fundraise, orderbook, and capex — for Earkart Limited and 1,400+ other companies.
Fundraise plans
- →There is no explicit mention of any current or planned new fundraising through debt or equity during the call.
- →Mr. Rohit Misra confirms that sufficient funds are already available following the recent IPO to support the planned expansion, including the installation of devices in clinics.
- →The company has made provisions to ensure the model becomes self-sustaining by the time of 350 installations.
- →No mention of additional debt or equity fundraising plans was discussed for future financing.
- →The focus is on efficient cash use and organic growth, leveraging the existing IPO proceeds for capex and expansion.
Order book
Yes- →Earkart has already secured government orders worth approximately ₹9 crores in the current fiscal year (Page 8, 7th excerpt).
- →Four government tenders, usually opening before September, were deferred but two have already opened, with 2-3 more expected to open in the second half of the fiscal year (Page 8).
- →The second half of the year is expected to see a significant scale-up in order inflows due to these tender openings (Page 8).
- →Private sector orders have grown by over 25% compared to last year, supporting overall revenue despite deferred government orders (Page 8).
- →The company aims for a 25% compound annual growth rate (CAGR) this year, driven by both government and private orders (Page 8).
- →No explicit total value of the full order book or pending orders beyond these notes was mentioned in the transcript.
Capex plans
Yes- The company has planned installation of around 500 to 550 clinics by the end of FY 2027.
- The installation cost per device is approximately ₹2.7 lakh per clinic.
- Recent IPO proceeds include unutilized funds sufficient to cover the capex for clinic installations.
- By the time 350 installations are achieved, the business model is expected to become self-sustaining.
- Expansion involves hiring more employees and setting up new infrastructure to support growth.
- Investments are also being made in improving the OMNI Audiometer for better efficiency and availability.
- Strategic expansion planned geographically from North India towards West, South, and eventually East India.
- Efforts include partnerships with financial institutions (e.g., zero pay NBFC) for interest-free EMI offerings to customers.
- Focus on reducing customer acquisition costs by positioning products within ENT practices.
Overall, a clear strategy of measured capital expenditure aligned with clinic expansion and technological improvements is in place.
How does Earkart Limited rank vs peers in Healthcare Equipment & Supplies?
Pro feature1Earkart Limited
Rev 2Mar 3
See full Healthcare Equipment & Supplies sector rankings
Unlock with ProWant more stocks like Earkart Limited?
Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.
Build my portfolio